BioSpace News Archive

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced it has completed enrollment of VIA-002, the company’s pivotal trial of the ViaLase® Laser to treat adult patients with primary open angle glaucoma (POAG).

Mozart Therapeutics today announced the expansion of its executive leadership team with the appointments of Jason Chien , MD, as Chief Medical Officer, and Russ Hawkinson as Chief Financial Officer.

Sonata Therapeutics, Inc. , a biotechnology company developing a new class of therapeutics called Network Medicines™, today announced it will be presenting three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Evident Vascular, Inc. announced today its Scientific Advisory Board and expansion of its Board of Directors.

BioXcel Therapeutics, Inc. announced that the Centers for Medicare & Medicaid Services has issued a permanent and product-specific J-Code for IGALMI™ sublingual film, which is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting and Eyecelerator @ AAO 2023 taking place in San Francisco, California.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Can-Fite BioPharma Ltd. announced that Biomolecules, a peer-reviewed scientific journal focused on function and mechanism of bioactive molecules, published an article titled “Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways”, authored by Can-Fite’s CSO Dr. Pnina Fishman and others.

Alterity Therapeutics Limited, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2023.

Hexiris Pharma Inc. is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.